Pharmaceutical

MesoCancerVac by Amphera for Metastatic Pancreatic Cancer: Likelihood of Approval

MesoCancerVac is under clinical development by Amphera and currently in Phase I for Metastatic Pancreatic Cancer.

Jul 7, 2023 - 20:00
MesoCancerVac is under clinical development by Amphera and currently in Phase I for Metastatic Pancreatic Cancer.
Read the original article

Tags:

Previous Article

Selinexor by Karyopharm Therapeutics for Osteosarcoma: Likelihood of Approval

Next Article

ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Long Covid research funding at NIH gets a nearly 50% boost

Long Covid research funding at NIH gets a nearly 50% boost

Feb 15, 2024

Opinion: Drug pricing and the ‘impossible trinity’ for patients

Opinion: Drug pricing and the ‘impossible trinity’ for ...

Jul 24, 2023

STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions

STAT+: ‘It’s like Groundhog Day’: The cancer drug short...

Jun 28, 2023